Transforming growth factor-β signal transduction and progressive renal disease

被引:88
作者
Cheng, JF [1 ]
Grande, JP [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Renal Patholphysiol Lab, Dept Lab Med & Pathol, Rochester, MN 55905 USA
关键词
transforming growth factor-beta; kidney; signaling; extra cellular matrix; progressive renal disease;
D O I
10.1177/153537020222701102
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
Transforming growth factor-beta (TGF-beta) superfamily members are multifunctional growth factors that play pivotal roles in development and tissue homeostasis. Recent studies have underscored the importance of TGF-beta in regulation of cell proliferation and extracellular matrix synthesis and deposition. TGF-beta signaling is initiated by ligand binding to a membrane-associated receptor complex that has serine/threonine kinase activity. This receptor complex phosphorylates specific Smad proteins, which then transduce the ligand-activated signal to the nucleus. Smad complexes regulate target gene transcription either by directly binding DNA sequences, or by complexing with other transcription factors or co-activators. There is extensive crosstalk between the TGF-beta signaling pathway and other signaling systems, including the mitogen-activated protein kinase pathways. The importance of TGF-beta in regulation of cell growth has been emphasized by recent observations that mutations of critical elements of the TGF-beta signaling system are associated with tumor progression in patients with many different types of epithelial neoplasms. TGF-beta has emerged as a predominant mediator of extracellular matrix production and deposition in progressive renal disease and in other forms of chronic tissue injury. In this overview, recent advances in our understanding of TGF-beta signaling, cell cycle regulation by TGF-beta, and the role of TGF-beta in progressive renal injury are highlighted.
引用
收藏
页码:943 / 956
页数:14
相关论文
共 253 条
[1]
The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy [J].
Al-Douahji, M ;
Brugarolas, J ;
Brown, PAJ ;
Stehman-Breen, CO ;
Alpers, CE ;
Shankland, SJ .
KIDNEY INTERNATIONAL, 1999, 56 (05) :1691-1699
[2]
ALEXANDROW MG, 1995, CANCER RES, V55, P1452
[3]
Angiotensin-converting enzyme inhibition attenuates proteinuria and renal TGF-β1 mRNA expression in rats with chronic renal disease [J].
Ali, SM ;
Laping, NJ ;
Fredrickson, TA ;
Contino, LC ;
Olson, BA ;
Anderson, K ;
Brooks, DP .
PHARMACOLOGY, 1998, 57 (01) :20-27
[4]
TGF-BETA RECEPTORS AND ACTIONS [J].
ATTISANO, L ;
WRANA, JL ;
LOPEZCASILLAS, F ;
MASSAGUE, J .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1994, 1222 (01) :71-80
[5]
AYO SH, 1990, AM J PATHOL, V136, P1339
[6]
BAGCHUS WM, 1990, AM J PATHOL, V137, P215
[7]
BAGCHUS WM, 1986, LAB INVEST, V55, P680
[8]
Bartram U, 2001, CIRCULATION, V103, P2745
[9]
CONTROL OF CELL PATTERN IN THE NEURAL-TUBE - REGULATION OF CELL-DIFFERENTIATION BY DORSALIN-1, A NOVEL TGF-BETA FAMILY MEMBER [J].
BASLER, K ;
EDLUND, T ;
JESSELL, TM ;
YAMADA, T .
CELL, 1993, 73 (04) :687-702
[10]
Serum induction of the collagen X promoter requires the Raf/MEK/ERK and p38 pathways [J].
Beier, F ;
LuValle, P .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 262 (01) :50-54